Abstract:Published results suggests that high adiponectin level may decrease the risk of breast cancer. However, available evidence on breast cancer is conflicting. Therefore a meta-analysis was performed to assess the association between blood adiponectin and breast cancer risk. PubMed database, Web of Science, Elsevier Science, Springer Link and bibliographies of retrieved articles were searched for epidemiological studies published up to March 2013. Meta-analysis was performed on the combined effect values (OR) as well as standardized mean difference (SMD) including 17 studies. Fixed or random effect pooled measure was selected on the basis of homogeneity test among studies. The publication bias was assessed by the Egger's regression asymmetry test and Begg's rank correlation test with Begg's funnel plot. Subgroup analyses and sensitivity analysis were also performed. A total of 13 studies involving 3578 breast cancer cases and 4363 controls contributed to the OR analysis. The high adiponectin level did not significantly affect breast cancer risk (OR=0.902, 95% CI=0.773-1.053). After excluding articles that were the key contributors to between-study heterogeneity, the OR of high adiponectin level was associated with decreased breast cancer risk (OR=0.838, 95% CI=0.744-0.943). There was a significantly association between high adiponectin level and postmenopausal breast cancer women (OR=0.752, 95% CI=0.604-0.936); and it was not associated with premenopausal breast cancer women (OR=0.895, 95% CI=0.638-1.256). The result of pooled measure on SMD was that the high adiponectin level was associated with decreased breast cancer risk (SMD= -0.348, 95% CI= -0.533-0.614) after excluding articles which were the key contributors to between-study heterogeneity. Our findings indicate that high adiponectin level might decrease the risk of postmenopausal breast cancer. More randomized clinical trials and observational studies are needed to confirm this association with underlying biological mechanisms in the future.

Adiponectin and hepatocarcinoma: a comprehensive review

Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy.

Effect of adiponectin on obesity-linked diseases

Adiponectin Receptor Agonist Effectively Suppresses Hepatocellular Carcinoma Growth

Research Progress on Cancer-Associated Fibroblasts in Hepatocellular Carcinoma

Relationship Between Adipocytes and Hematological Tumors in the Bone Marrow Microenvironment: a Literature Review

Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk

Circulating Adiponectin And Risk Of Endometrial Cancer

Research progresses on the role of adiponectin and its receptors in prostate cancer

Circulating Adiponectin Levels in Various Malignancies: an Updated Meta-Analysis of 107 Studies

Tumor-Associated Neutrophils: an Emerging Player in the Immune Microenvironment of Hepatocellular Carcinoma

Adiponectin Suppresses Human Pancreatic Cancer Growth Through Attenuating The Beta-Catenin Signaling Pathway

The Role of Adiponectin in Breast Cancer: A Meta-Analysis

Role of adipocytokines in endometrial cancer progression

Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma

Adiponectin-Induced Antitumor Activity on Prostatic Cancers Through Inhibiting Proliferation

Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers

Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase

Adiponectin As a Negative Regulator in Obesity-Related Mammary Carcinogenesis

Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies

Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis